ACT recently completed its 6th FDA inspection in the last three consecutive years for high enrollment with no violations.
Anaheim, California (January 4, 2018) -- Anaheim Clinical Trials (ACT), an adult and pediatric Phase I through Phase IV clinical research center with full-service CRO capabilities, recently completed its 6th FDA inspection in the last three consecutive years for high enrollment with no violations. No FDA 483 was issued.
“ACT has one of the most rigorous QA programs in place to ensure that our sponsors and subjects are provided the quality standards they deserve and expect every time,” said Patrick McLaughlin, CEO. “Our QA staff is highly qualified and dedicated to providing a high degree of clinical research excellence.”
“QA is an integral part of our clinical study team,” added Dr. Peter Winkle, M.D., F.A.C.G, F.A.C.P., C.P.I., Medical Director. “Along with our nurses, doctors, and pharmacists, QA plays a key role in the conduct of each study we perform at ACT.”
About Anaheim Clinical Trials
Anaheim Clinical Trials (ACT) is an adult and pediatric Phase I clinical research center with full-service CRO capabilities, located in southern California (Anaheim). In addition to healthy volunteers, ACT has been particularly successful in enrolling special patient populations in complex trials and Japanese subjects for ethno-bridging trials. Our certified Principal Investigators have the expertise and interest in a wide variety of therapeutic areas, including GI, CNS, pain, metabolic/inflammation, infectious disease, and respiratory. ACT has been recognized by our customers for excellent quality research, timeliness, high patient enrollment, and ease of doing business. For more information about ACT, please visit our website at http://act-trials.com.
For more information, please contact Linda Gundaker, Executive Vice President, via email at lgundaker@act-trials.com or mobile at 610-937-2006.
